RT Journal Article
SR Electronic
T1 Patient-derived mutations impact pathogenicity of SARS-CoV-2
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.14.20060160
DO 10.1101/2020.04.14.20060160
A1 Yao, Hangping
A1 Lu, Xiangyun
A1 Chen, Qiong
A1 Xu, Kaijin
A1 Chen, Yu
A1 Cheng, Linfang
A1 Liu, Fumin
A1 Wu, Zhigang
A1 Wu, Haibo
A1 Jin, Changzhong
A1 Zheng, Min
A1 Wu, Nanping
A1 Jiang, Chao
A1 Li, Lanjuan
YR 2020
UL http://medrxiv.org/content/early/2020/04/22/2020.04.14.20060160.abstract
AB The sudden outbreak of the severe acute respiratory syndrome–coronavirus (SARS-CoV-2) has spread globally with more than 1,300,000 patients diagnosed and a death toll of 70,000. Current genomic survey data suggest that single nucleotide variants (SNVs) are abundant. However, no mutation has been directly linked with functional changes in viral pathogenicity. We report functional characterizations of 11 patient-derived viral isolates. We observed diverse mutations in these viral isolates, including 6 different mutations in the spike glycoprotein (S protein), and 2 of which are different SNVs that led to the same missense mutation. Importantly, these viral isolates show significant variation in cytopathic effects and viral load, up to 270-fold differences, when infecting Vero-E6 cells. Therefore, we provide direct evidence that the SARS-CoV-2 has acquired mutations capable of substantially changing its pathogenicity.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by funds from Major Project of Zhejiang Provincial Science and Technology Department #2020C03123, National Science and Technology Major Project for the Control and Prevention of Major Infectious Diseases in China (2018ZX10711001, 2018ZX10102001, 2018ZX10302206), and start-up funds from Life Sciences Institute at Zhejiang University;Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe full-genome sequences of the 11 viral isolates have been deposited to the GISAID collection with the following IDs: EPI_ISL_415709, EPI_ISL_416042, EPI_ISL_416044, EPI_ISL_416046, EPI_ISL_415711, EPI_ISL_416047, EPI_ISL_416425, EPI_ISL_416473, EPI_ISL_416474, EPI_ISL_418990, and EPI_ISL_418991.